Comparative efficacy of Haridrakhanda and Haridrakhanda without milk in Sheetapitta

Phase 3

Completed

• Conditions: Health Condition 1: L00-L99- Diseases of the skin and subcutaneous tissueHealth Condition 2: L50- UrticariaHealth Condition 3: L50- UrticariaHealth Condition 4: L50- Urticaria

• Registration Number: CTRI/2020/04/024439
• Lead Sponsor: IPGT and RA

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Completion: 2021-03-06
• Last Update Posted: 24 November 2021

Recruitment & Eligibility

• Status: Completed
• Sex: Not specified
• Target Recruitment: 60

Inclusion Criteria

(1)Patients with all forms of Sheetapitta (Urticaria) with classical signs & symptoms of Sheetapitta (Urticaria).

(2)Age- 18 to 60 years.

(3)Gender- Both Males and females.

(4)All types of Urticaria will be included (with chronicity of more than 8 weeks and frequency of wheals and flares not less than twice/week or 10 times/month) without any medicine or requiring medications for urticaria atleast twice weekly to remain asymptomatic.

Exclusion Criteria

(1)Age <18yrs & >60yrs.

(2)Pregnant women

(3)Giant Urticaria, Angioedema, History of anaphylaxis

(4)Uncontrolled Diabetes Mellitus

(5)Any other serious systemic illness like AIDS, Malignancy etc

(6)Patients who are not willing to get included in the study

(7)Severe anemia (Hb <7gm/dl)

(8)Widespread dermatological infections, Parasitic infections

(9)Patients with conditions significantly exaggerating urticaria/itching e.g. severe Photosensitivity leading to photodermatitis, Albinism, extensive vitiligo, Severe extensive eczema.

(10)Known cases of Hyperbilirubinemia, Hypothyroidism, Cases of alcoholism.

(11)Drug induced urticaria, urticaria due to recent onset contact dermatitis.

(12)Patients on drugs with possible interference with urticaria like penicillins, antiallergic drugs like antihistaminics, systemic steroids, mast cell stabilizers, Histamine 2 receptor blockers, adrenergics, decongestants, tranquilizers (tricyclic antidepressants), Salicylates, ACE inhibitors etc for other associated conditions and these conditions which may require above cited drugs as part of management.

Study & Design

• Study Type: Interventional
• Study Design: Not specified